| Dr Keith Bernard Parish, MD | |
|
2503 John Hawkins Pkwy Ste 105, Hoover, AL 35244-3514 | |
| (205) 987-6801 | |
| Not Available |
| Full Name | Dr Keith Bernard Parish |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 31 Years |
| Location | 2503 John Hawkins Pkwy Ste 105, Hoover, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487713343 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 10679R (Louisiana) | Secondary |
| 207P00000X | Emergency Medicine | MD27914 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grandview Medical Center | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alabama Healthcare Development Llc | 9739283813 | 2 |
News Archive
In a surprising development, a research team led by the National Human Genome Research Institute (NHGRI), has found that a class of experimental anti-cancer drugs also shows promise in laboratory studies for treating a fatal genetic disorder that causes premature aging.
Gero Miesenböck was the first to insert a light-controlled on/off switch into brain cells. His pioneering method allows scientists to switch nerve cells on and off selectively and observe how the behaviour of, for example, fruit flies or mice changes as a result. In this way, researchers can learn in a step-by-step process what behaviour the studied brain circuits control and what goes awry in disease. For his method, hailed as a "breakthrough of the decade," Professor Gero Miesenböck of the University of Oxford will receive the 100,000-euro Heinrich Wieland Prize of the Boehringer Ingelheim Foundation in Munich on November 6, 2015.
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University of Georgia.
› Verified 1 days ago
| Entity Name | Alabama Healthcare Development Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346309663 PECOS PAC ID: 9739283813 Enrollment ID: O20070329000235 |
News Archive
In a surprising development, a research team led by the National Human Genome Research Institute (NHGRI), has found that a class of experimental anti-cancer drugs also shows promise in laboratory studies for treating a fatal genetic disorder that causes premature aging.
Gero Miesenböck was the first to insert a light-controlled on/off switch into brain cells. His pioneering method allows scientists to switch nerve cells on and off selectively and observe how the behaviour of, for example, fruit flies or mice changes as a result. In this way, researchers can learn in a step-by-step process what behaviour the studied brain circuits control and what goes awry in disease. For his method, hailed as a "breakthrough of the decade," Professor Gero Miesenböck of the University of Oxford will receive the 100,000-euro Heinrich Wieland Prize of the Boehringer Ingelheim Foundation in Munich on November 6, 2015.
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University of Georgia.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Keith Bernard Parish, MD 2503 John Hawkins Pkwy Ste 105, Hoover, AL 35244-3514 Ph: (205) 987-6801 | Dr Keith Bernard Parish, MD 2503 John Hawkins Pkwy Ste 105, Hoover, AL 35244-3514 Ph: (205) 987-6801 |
News Archive
In a surprising development, a research team led by the National Human Genome Research Institute (NHGRI), has found that a class of experimental anti-cancer drugs also shows promise in laboratory studies for treating a fatal genetic disorder that causes premature aging.
Gero Miesenböck was the first to insert a light-controlled on/off switch into brain cells. His pioneering method allows scientists to switch nerve cells on and off selectively and observe how the behaviour of, for example, fruit flies or mice changes as a result. In this way, researchers can learn in a step-by-step process what behaviour the studied brain circuits control and what goes awry in disease. For his method, hailed as a "breakthrough of the decade," Professor Gero Miesenböck of the University of Oxford will receive the 100,000-euro Heinrich Wieland Prize of the Boehringer Ingelheim Foundation in Munich on November 6, 2015.
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University of Georgia.
› Verified 1 days ago
Dr. Shelly Rhodes Weisenfeld, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 774 Shades Mountain Plz, Hoover, AL 35226 Phone: 205-979-3381 | |
Mohamed Hassan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5569 Grove Blvd, Hoover, AL 35226 Phone: 205-637-2600 | |
Dr. Nilam Chiman Patel, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2427 Glasscott Pt, Hoover, AL 35226 Phone: 205-223-9537 | |
Dr. Annamalai Nadarajan Jr., MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2698 Montauk Rd, Hoover, AL 35226 Phone: 251-545-6365 | |
Timothy Blake Lovely, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1575 Montgomery Hwy, Hoover, AL 35216 Phone: 205-330-1707 | |
Dr. Richard Lowell Grantier Iii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4517 Southlake Pkwy, Hoover, AL 35244 Phone: 205-985-4111 |